CACA guidelines for holistic integrative management of adult acute myeloid leukemia
-
Published:2024-03-14
Issue:1
Volume:3
Page:
-
ISSN:2731-4529
-
Container-title:Holistic Integrative Oncology
-
language:en
-
Short-container-title:Holist Integ Oncol
Author:
Wei Hui, Mi Yingchang, Wang Ying, Jiang Erlie, Hu Jianda, Yan Xiaojing, Han Yanqiu, Lai Yongrong, You Yong, Gao Sujun, Gao Chunji, Xu Bing, Yu Wenjuan, Chen Jieping, Chen Suning, Gong Tiejun, Yang Linhua, Yang Jianmin, Du Xin, Du Xin, Li Wei, Li Fei, Li Yan, Li Jian, Li Junmin, Jin Jie, Zhang Xi, Zhang Mei, Zhang Yu, Zhang Guangsen, Song Xianmin, Song Yongping, Jiang Qian, Wu Tong, Liu Ting, Liu Zhuogang, Liu Daihong, Ren Hanyun, Feng Ru, Fu Rong, Zhu Honghu, Sun Zimin, Wang Jianmin, Wang Xin, Wang Jishi, Wang Shaoyuan, Fang Meiyun, Huang He, Hu Yu, Liu Qifa, Ma Jun, Shen Zhixiang, Wu Depei, Huang Xiaojun, Zhou Jianfeng, Ji Chunyan, Qiu Lugui, Li Jianyong, Wang JianxiangORCID
Abstract
AbstractThe CACA Guidelines was summarized by Hematology Oncology Committee of China Anti- Cancer Association. This portion of the CACA Guidelines for adult acute myeloid leukemia (AML) not only focuses on diagnosis, the treatment options for younger (age < 60 years) and older (age ≥ 60 years) patients (including non-APL, APL, R/R AML), but also pay attention to the treatment of AML complications, including central nervous system leukemia (CNSL), cardiotoxicity, agranulocytosis and fever, hepatitis B virus reactivation, uric acid nephropathy, bleeding and coagulation disorders, and nursing for patients with AML from the perspective of holistic integrative medicine to enhance the quality of life and treatment effects.
Funder
the National Key Research and Development Program of China CAMS Innovation Fund for Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. 2. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. 3. Mi Y, Xue Y, Yu W, et al. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leuk Lymphoma. 2008;49(3):524–30. 4. Jin J, Wang J-X, Chen F-F, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14(7):599–608. 5. Wei H, Zhou C, Lin D, et al. Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia. Haematologica. 2020;106(5):1491–5.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|